Sanofi EFC14868 A Randomized, Double-blind, Placebo-controlled, Parallel-group, 52-week Multicenter Study to Evaluate the Efficacy and Safety of Sotagliflozin in Patients with Type 2 Diabetes Who Have Inadequate Glycemic Control on Basal Insulin Alone or in Addition to Oral Antidiabetes Drugs (OADs)

June 28, 2018
https://clinicaltrials.gov/ct2/show/NCT03285594
Diabetes
Principal Investigator: Arti Bhan, MD
Diabetes, Type 2, Type 2 Diabetes
In Progress